Review of NHANES data links metformin use to lower mortality and inflammatory markers in type 2 diabetes

Metformin has been linked to mortality benefits in type 2 diabetes that may extend beyond glycemic control, but population-level evidence connecting these benefits to inflammation-related pathways remains limited. Using NHANES 2013-2018 data with mortality follow-up through 2019, we examined associations between metformin use and four inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), serum albumin, and high-sensitivity C-reactive protein (hs-CRP), and evaluated their relevance to all-cause and cardiovascular mortality. Among 2,122 adults with self-reported diabetes (60% metformin users; 2,116 with valid mortality follow-up), survey-weighted linear regression adjusted for demographic, socioeconomic, and metabolic covariates showed metformin use was associated with lower NLR ({beta} = -0.35; 95% CI -0.57, -0.14), lower MLR ({beta} = -0.04; 95% CI -0.06, -0.02), and higher serum albumin ({beta} = +0.11 g/dL; 95% CI 0.06, 0.16); the hs-CRP association was directionally consistent but not significant. Associations for NLR and MLR were essentially unchanged after BMI and HbA1c adjustment, remained robust in an active comparator analysis against sulfonylurea monotherapy, and were consistent across propensity score and overlap weighting sensitivity analyses. Survey-weighted Cox regression linked metformin to lower all-cause (HR 0.64; 95% CI 0.48, 0.86) and cardiovascular mortality (HR 0.49; 95% CI 0.26, 0.94). NLR was independently associated with all-cause mortality, with the highest tertile carrying nearly twice the hazard of the lowest, and inclusion of NLR or MLR modestly attenuated the metformin-mortality association. Metformin use is associated with a distinct cellular immune-inflammation profile in adults with type 2 diabetes, supporting further investigation of non-glycemic pathways relevant to its long-recognized clinical benefits.